ASX CODE: IXHL

Incannex Healthcare NASDAQ IXHL 42X obstructive sleep apnea phase 2 clinical trial OSA AHI

Incannex Healthcare’s IHL-42X lowered apnea hypopnea index score in OSA sufferers during clinical study

Incannex Healthcare (NASDAQ: IXHL, ASX: IHL) has found its drug IHL-42X reduced the apnea hypopnea index (AHI) score at the three doses it was given to obstructive sleep apnea (OSA) patients during a ...
Incannex Healthcare NASDAQ IXHL ASX US Food and Drug Administration FDA IHL-42X treat obstructive sleep apnoea OSA

Incannex meets with US FDA on development of IHL-42X to treat obstructive sleep apnoea

Clinical-stage cannabinoid pharmaceutical development company Incannex Healthcare (NASDAQ: IXHL) (ASX: IHL) has completed a pre-investigational new drug application (pre-IND) meeting with the US Food ...
Incannex Healthcare NASDAQ IXHL APIRx Pharmaceuticals acquisition medicinal cannabinoid CBD drugs psychedelic

Incannex Healthcare closes in on completing APIRx Pharmaceuticals acquisition

Incannex Healthcare (NASDAQ: IXHL, ASX: IHL) has completed the share sale and purchase agreement to acquire APIRx Pharmaceuticals, which will form “the world’s largest portfolio” of patented medicinal...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS